AbbVie has filed a complaint against Amgen related to AbbVie’s Humira (adalimumab). The complaint asserts patent infringement and also seeks a declaratory judgment to compel Amgen to comply with the BPCIA’s notice of commercial marketing provision.
Stay tuned to Big Molecule Watch for more details later today.
The post Breaking News: AbbVie Files Complaint Against Amgen appeared first on Big Molecule Watch.